1-8 of 8
Dawn Trueman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Elodie Montaudon, Heloise Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin-Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3989–4004.
https://doi.org/10.1158/0008-5472.CAN-23-0694
Published: 01 December 2023
View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Open the PDF for The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Mandy Lawson, Natalie Cureton, Michelle DuPont, Oona Delpuech, Dawn Trueman, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Jamie Scott, Teresa Klinowska, Christopher J. Morrow
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4379.
https://doi.org/10.1158/1538-7445.AM2020-4379
Published: 15 August 2020
View article titled, Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant
Journal Articles

Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development

Pablo Morentin Gutierrez, Christopher Morrow, Natalie Cureton, Mandy Lawson, Dawn Trueman, Eric Gangl, Joanne Wilson, Aaron Smith, James Scott, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4369.
https://doi.org/10.1158/1538-7445.AM2020-4369
Published: 15 August 2020
View article titled, Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development
Journal Articles

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Mandy Lawson, Natalie Cureton, Oona Delpuech, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Dawn Trueman, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Teresa Klinowska, Christopher J Morrow
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-04-15.
https://doi.org/10.1158/1538-7445.SABCS19-P6-04-15
Published: 15 February 2020
View article titled, Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects
Journal Articles

Abstract 3769: Continuous, low intensity systemic dosing maximizes the therapeutic margin of Eg5/KSP inhibition in an orthotopic model of urothelial cell carcinoma

Leigh Williams, Rebecca Ellston, Dawn Trueman, Helen Musgrove, Linette Ruston, Brian Aquila, Elizabeth Pease, Stephanie Klein, Barry R. Davies
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3769.
https://doi.org/10.1158/1538-7445.AM2016-3769
Published: 15 July 2016
View article titled, Abstract 3769: Continuous, low intensity systemic dosing maximizes the therapeutic margin of Eg5/KSP inhibition in an orthotopic model of urothelial cell carcinoma
Journal Articles

Abstract 5146: Establishment of an orthotopic bladder cancer model to evaluate continuous intravesical delivery of small molecule inhibitors in the nude rat

Leigh J. Williams, Stephanie K. Klein, Danielle Greenawalt, Dawn Trueman, Helen Musgrove, Helen Jones, Linette Ruston, Barry R. Davies
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5146.
https://doi.org/10.1158/1538-7445.AM2015-5146
Published: 01 August 2015
View article titled, Abstract 5146: Establishment of an orthotopic bladder cancer model to evaluate continuous intravesical delivery of small molecule inhibitors in the nude rat
Journal Articles

Abstract 5409: AZD1152-hQPA Accurins: Nanoparticle formulations showing extended release and the potential for improved therapeutic index

Simon T. Barry, Elaine Cadogan, Rajesh Odedra, Susan Ashton, John Foster, Young Ho Song, Susan Low, Paula Taylor, Rebecca Ellston, Urszula Polanska, Joanne Wilson, Colin Howes, Dawn Trueman, Mike Walker, David De Witt, Marianne Ashford, Jeff Hrkach, Phil Jewsbury
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5409.
https://doi.org/10.1158/1538-7445.AM2014-5409
Published: 01 October 2014
View article titled, Abstract 5409: AZD1152-hQPA Accurins: Nanoparticle formulations showing extended release and the potential for improved therapeutic index
Journal Articles

Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer

Sarah A. Loddick, Rob Bradbury, Nicola Broadbent, Hayley Campbell, Luke Gaughan, Jim Growcott, Natalie Stratton, Elizabeth Mouchet, Daniel O'Neill, Al Rabow, David Robinson, Craig N. Robson, Sarah J. Ross, Fadhel Shaheen, Dawn Trueman, Graeme Walker, Stephen R. Wedge, Nigel A.N. Brooks
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3848.
https://doi.org/10.1158/1538-7445.AM2012-3848
Published: 15 April 2012
View article titled, Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer